More Information

Ketan D. Patel

Assistant Professor
Pharmaceutical Sciences
Dr. Ketal Patel joined St. John’s University as an Assistant Professor of Pharmaceutics in September 2016. He holds PhD in Pharmaceutics from Institute of Chemical Technology (formerly UDCT), Mumbai, India (2013); M.Pharm from Mumbai University, India (2009) and B.Pharm from Sardar Patel University, India (2007). He was awarded AICTE and UGC-SAP fellowships for securing all India first rank in Graduate Aptitude Test in Engineering (GATE)-2007 and ICT PhD entrance test-2009, respectively. Post completion of his PhD, he joined Department of Pharmaceutical Sciences, Florida A&M University, FL, USA as a Postdoctoral Fellow on an NIH-funded research project. During his postdoctoral tenure (Jan. 2014 - June 2016), he worked on various projects; Targeted nanotherapeutics for lung & breast cancer treatment, overcoming drug resistant in lung cancer, topical formulations for chemoprevention & psoriasis treatment. During, his PhD and postdoc, he has received a number of oral/poster/travelship awards for presenting his research work at various international conferences including AAPS, CRS, ACCP, GRASP and IPC. Dr. Patel has authored 20 publications in peer-reviewed journals in the field of Pharmaceutics, Nanomedicine and Cancer. He has filed 3 US patents for his innovative formulation pertaining to the treatment of cancer and psoriasis. He recently received Melanoma Research Scholar Award for his research proposal on metastatic melanoma targeted nanomedicine. Currently, he is guiding two graduate and two master’s students working in the area of cancer nanotechnology (Melanoma, Pancreatic cancer), 3D printing and solubility and bioavailability enhancement techniques.

Teaching Interests

Pharmaceutics, Extemporaneous compounding, Biopharmaceutics

Research Interests

A. Tumor targeted nanotherapeutics for the treatment of melanoma and pancreatic cancer B. Solubility and bioavailability enhancement of anti-diabetic and anti-hyperlipidamic class of drugs using liquisolid technique, Hot Melt Extrusion and 3D printin

Courses Taught


Select Publications

Journal Articles

Boakye, C. H., Patel, K. D., Doddapaneni, R., Bagde, A., Marepally, S., and Singh, M. (2017). Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment. Journal of Controlled Release. vol. 246, pp. 120–132.

Patel, K. D., Doddapaneni, R., Chowdhury, N., Boakye, C. H., Behl, G., and Singh, M. (2016). Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. Nanomedicine. vol. 11, pp. 1377–1392.

Patel, K. D., Doddapaneni, R., Sekar, V., Chowdhury, N., and Singh, M. (2016). Combination approach of YSA peptide anchored docetaxel stealth liposomes with oral antifibrotic agent for the treatment of lung cancer. Molecular pharmaceutics. vol. 13, pp. 2049–2058.

Doddapaneni, R., Patel, K. D., Owaid, I. H., and Singh, M. (2016). Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer. Drug delivery. vol. 23, pp. 1232–1241.

Doddapaneni, R., Patel, K. D., Chowdhury, N., and Singh, M. (2016). Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. Experimental cell research. vol. 346, pp. 65–73.

Lacey, A., Hedrick, E., Li, X., Patel, K. D., Doddapaneni, R., Singh, M., and Safe, S. (2016). Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS). Oncotarget. vol. 7, pp. 31257.

Cheriyan, V. T., Muthu, M., Patel, K. D., Sekhar, S., Rajeswaran, W., Larsen, S. D., Polin, L., Levi, E., Singh, M., and Rishi, A. K. (2016). CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers. Oncotarget. vol. 7, pp. 73370.

Boakye, C. H., Patel, K. D., Patel, A. R., Faria, H. A., Zucolotto, V., Safe, S., and Singh, M. (2016). Lipid-based oral delivery systems for skin deposition of a potential chemopreventive DIM derivative: characterization and evaluation. Drug Delivery and Translational Research. vol. 6, pp. 526–539.

Boakye, C. H., Patel, K. D., Doddapaneni, R., Bagde, A., Behl, G., Chowdhury, N., Safe, S., and Singh, M. (2016). Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemoprevention. Colloids and Surfaces B: Biointerfaces. vol. 143, pp. 156–167.

Patel, K. D., Chowdhury, N., Doddapaneni, R., Boakye, C. H., Godugu, C., and Singh, M. (2015). Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. Journal of pharmaceutical sciences. vol. 104, pp. 4417–4426.

Boakye, C. H., Patel, K. D., and Singh, M. (2015). Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers. International journal of pharmaceutics. vol. 489, pp. 106–116.

Patel, K. D., Patil, A., Mehta, M., Gota, V., and Vavia, P. (2014). Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity. International journal of pharmaceutics. vol. 472, pp. 214–223.

Patel, K. D., Patil, A., Mehta, M., Gota, V., and Vavia, P. (2013). Medium chain triglyceride (MCT) rich, paclitaxel loaded self nanoemulsifying preconcentrate (PSNP): a safe and efficacious alternative to Taxol®. Journal of biomedical nanotechnology. vol. 9, pp. 1996–2006.

Cancer Nanotechnology
3D printing
Solubility enhancement